Indications for: ARTESUNATE FOR INJECTION
Initial treatment of severe malaria.
Limitations of Use:
Not for treating the hypnozoite liver stage forms of Plasmodium and therefore not prevent relapses of malaria due to Plasmodium vivax or Plasmodium ovale.
Adults and Children:
<6months: not established. Give by slow IV bolus inj over 1–2mins. ≥6months: 2.4mg/kg at 0hr, 12hrs, and 24hrs, and thereafter given once daily until able to tolerate oral antimalarial therapy. Complete treatment course with an appropriate oral antimalarial regimen (eg, an 8-aminoquinoline).
ARTESUNATE FOR INJECTION Warnings/Precautions:
Monitor for post-treatment hemolytic anemia for 4 weeks. Consider discontinuation if hypersensitivity reactions occur; use alternative treatment. Pregnancy. Nursing mothers.
ARTESUNATE FOR INJECTION Classification:
ARTESUNATE FOR INJECTION Interactions:
May be potentiated by strong UGT inhibitors (eg, axitinib, vandetanib, imatinib, diclofenac); monitor. May be antagonized by ritonavir, nevirapine, or strong UGT inducers (eg, rifampin, carbamazepine, phenytoin); monitor for possible reduced efficacy if used concomitantly.
Acute renal failure requiring dialysis, hemoglobinuria, jaundice, anemia, increased transaminase, thrombocytopenia, hyperbilirubinemia, leukocytosis, acute respiratory distress syndrome, lymphopenia, neutropenia.
Generic Drug Availability:
Single-dose vial—1, 4 (w. diluent)